Aptose Biosciences Inc. Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
Aptose Biosciences Inc. quarterly/annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect history and growth rate from Q1 2017 to Q3 2024.
  • Aptose Biosciences Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending September 30, 2024 was -$368K, a 105% decline year-over-year.
  • Aptose Biosciences Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the twelve months ending September 30, 2024 was -$7.76M, a 36.8% increase year-over-year.
  • Aptose Biosciences Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was -$27.7M, a 1193% decline from 2022.
  • Aptose Biosciences Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2022 was -$2.14M, a 97.3% increase from 2021.
  • Aptose Biosciences Inc. annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2021 was -$78.3M, a 308% decline from 2020.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Trailing 12 Months (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$7.76M -$368K -$7.69M -105% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$70K $984K +$15.3M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$15.4M -$1.91M +$12.3M +86.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$27.7M -$6.47M -$15.4M -172% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-26
Q3 2023 -$12.3M $7.32M +$19.4M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$31.6M -$14.4M -$17.4M -572% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$14.2M -$14.2M -$12.1M -569% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$2.14M $8.98M +$45M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-26
Q3 2022 -$47.1M -$12M -$3.8M -46% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$43.3M $3.04M +$6.78M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$50.1M -$2.12M +$28.2M +93% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 -$78.3M -$36M -$53.6M -304% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-24
Q3 2021 -$24.6M -$8.25M -$53.9M -118% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 $29.2M -$3.74M +$1.9M +33.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-02
Q1 2021 $27.3M -$30.3M -$10.2M -50.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $37.6M $17.7M -$41.5M -70.1% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-22
Q3 2020 $79M $45.6M +$51.8M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $27.2M -$5.64M -$16M -155% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $43.2M -$20.1M -$21.4M -1667% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 $64.5M $59.2M +$58.9M +24244% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-23
Q3 2019 $5.63M -$6.21M -$3.32M -115% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 $8.95M $10.3M +$7.78M +307% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $1.17M $1.28M -$3.5M -73.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q4 2018 $4.67M $243K -$2.49M -91.1% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-10
Q3 2018 $7.15M -$2.89M -$2.86M -8925% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 $10M $2.54M +$3.59M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $6.42M $4.78M +$3.73M +354% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 $2.69M $2.73M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 -$32K Jul 1, 2017 Sep 30, 2017 8-K 2019-03-12
Q2 2017 -$1.06M Apr 1, 2017 Jun 30, 2017 8-K 2019-03-12
Q1 2017 $1.05M Jan 1, 2017 Mar 31, 2017 8-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.